Tafluprost is well-tolerated and reduces intraocular pressure in healthy volunteers, according to results from a phase I study.* Sixteen healthy volunteers received sequentially increasing dosages of 0.0001–0.005% tafluprost in one eye, and placebo in the other eye; administration of each tafluprost dosage level was separated by at least 5 days. Only one volunteer experienced an adverse event that was associated with treatment. Tafluprost was associated with reduced intraocular pressure, compared with placebo, and the between-group differences were significant for the 0.0005%, 0.0025% and 0.005% concentrations. The maximum effect of treatment with tafluprost occurred within 12 hours of administration.

* This study was supported by Santen Oy.